Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | THPO | P40225 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975578 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL29617834 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL314051 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL9294393 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL18521420 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL314052 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL23621389 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL21063207 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL21625242 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL25748736 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 707 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-09-14 | — | — | US | disclosed |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | JANSSEN BIOTECH, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3724205-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| EP-3823976-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | Janssen Biotech, Inc. (US) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020016782-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2020-01-23 | — | — | WO | disclosed |
| EP-2270024-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180094260-A1 | EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS | KASTLE THERAPEUTICS, LLC (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170355986-A1 | ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION | KASTLE THERAPEUTICS, LLC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9476051-B2 | Antisense modulation of superoxide dismutase 1, soluble expression | IONIS PHARMACEUTICALS, INC. (US) | 2016-10-25 | — | — | US | disclosed |
| US-5962672-A | OLIGONUCLEOTIDES AGAINST NUCLEIC ACID WHICH CODES FOR SMALL GUANOSINE TRIPHOSPHATASE IMPORTANT IN REGULATION OF CYTOSKELETON DURING CELL CYCLE; FOR ANTICARCINOGENIC/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962671-A | OLIGONUCLEOTIDE WHICH SUPPRESSES GENE EXPRESSION OF FACTOR ASSOCIATED WITH NEUTRAL SPHINGOMYELINASE ACTIVATION; FACTOR IS IS A MEDIATOR OF TUMOR NECROSIS FACTOR ACTIVATION OF THAT ENZYME THROUGH A SIGNAL TRANSDUCTION PATHWAY; GENE THERAPY | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5962673-A | ANTISENSE AGENT 8 TO 30 NUCLEOBASES IN LENGTH; FOR DIAGNOSIS AND TREATMENT OF ASTHMA, MYASTHENIA GRAVIS, GRAVES' DISEASE, ALLOGRAFT REJECTION, PSORIASIS AND OTHERS; ANTITUMOR/ ANTIPROLIFERATIVE/ANTIDIABETIC/ANTIARTHRITIC AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-10-05 | — | — | US | disclosed |
| US-5958771-A | OLIGONUCLEOTIDE FROM 8 TO 30 NUCLEOTIDES IN LENGTH; FOR DIAGNOSIS AND THERAPY; ANTITUMOR/ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958772-A | TARGETS TO NUCLEIC ACID MOLECULE ENCODING HUMAN CELLULAR INHIBITORS OF APOTOPSIS-1 | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5958773-A | ANTISENSE COMPOUND 8 TO 30 NUCLEOTIDES IN LENGTH TARGETED TO A NUCLEIC ACID ENCODING HUMAN AKT-1, OF THE SERINE/THREONINE KINASE FAMILY INVOLVED IN SIGNALLING PATHWAYS; INHIBITING EXPRESSION OF AKT-1 WITH THE ANTISENSE COMPOUND | ISIS PHARMACEUTICALS INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5959097-A | OLIGONUCLEOTIDE OF 8 TO 30 NUCLEOTIDES WHICH SUPPRESSES EXPRESSION OF SIGNAL TRANSDUCTION KINASE; FOR TREATMENT OF INFECTIONS; ANTIINFLAMMATORY/ANTITUMOR AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5951455-A | OLIGONUCLEOTIDES, TARGETED TO NUCLEIC ACIDS WITH MODULATION AND EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1999-09-14 | — | — | US | disclosed |
| US-5948680-A | ANTISENSE OLIGONUCLEOTIDE TARGETED TO NUCLEIC ACIDS ENCODING ELK-1; ANTIPROLIFERATIVE AGENTS | ISIS PHARMACEUTICALS INC. (US) | 1999-09-07 | — | — | US | disclosed |
| US-5945290-A | OLIGONUCLEOTIDES TARGETED AGAINST SPECIFIC NUCLEIC ACIDS; FOR ANTITUMOR/ANTICARCINOGENIC AGENTS; DIAGNOSIS AND THERAPY OF RELATED DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287034-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | LMNA 659/4885SLC29A1 2172/4885TSHR 2168/4885 |
| US-20210277046-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | LMNA 653/4885SLC29A1 2152/4885TSHR 2323/4885 |
| US-11597746-B2 | Cyclic dinucleotides as sting agonists | STING1, CGAS, IFNAR1 | LMNA 653/4885SLC29A1 2152/4885TSHR 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.